Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02737085
Recruitment Status : Active, not recruiting
First Posted : April 13, 2016
Last Update Posted : September 7, 2016
Sponsor:
Information provided by (Responsible Party):
Jieping Chen, Southwest Hospital, China

Brief Summary:
The main purpose of this study is to explore the sequential therapeutic effect of CD19-targeted and CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Diffuse Large B Cell Lymphoma(DLBCL)

Condition or disease Intervention/treatment Phase
Lymphoma, Large B-Cell, Diffuse Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells Phase 1 Phase 2

Detailed Description:
The anti-CD20 antibody has been broadly used in the treatment of B cell malignancies and exhibited good clinical outcomes. The CD19-targeted CAR-T has shown excellent therapeutic efficiency in B cell malignancies,especially in acute lymphocytic leukemia. However, patients treated with CD19-targeted CAR-T may face relapse of CD19 mutation. Therefore we attempt to treat Diffuse Large B Cell Lymphoma(DLBCL) patients by sequential therapy of the 2 targets and hope to combine their advantages.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
Study Start Date : March 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Rituximab

Arm Intervention/treatment
Experimental: Diffuse Large B Cell Lymphoma(DLBCL)
The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
Other Name: CD19-targeted CAR-T cells and CD20-targeted CAR-T cells




Primary Outcome Measures :
  1. Adverse Events That Are Related to Treatment [ Time Frame: 2 years ]
    Determine the toxicity profile of the CD19-targeted and CD20-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. CD19-expressing and CD20-expressing Diffuse Large B Cell Lymphoma(DLBCL) must be assured and must be relapsed or refractory disease after at least one standard chemotherapy and one salvage regimen. According to current traditional therapies, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have disease activity that prohibits SCT at this time.
  2. Patients enrolled must have an evaluated score above 60 with KPS.
  3. Expected survival time of patients enrolled is over 3 months.
  4. Gender is not limited, age from 14 years to 75 years.
  5. Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
  6. Patients are expected to survive for more than 3 months by their physicians at the time of enrollment.
  7. Adequate absolute CD3 count estimated need to be assured for obtaining target cell dose based on dosage cohorts.
  8. Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)
  9. Patients with isolated CNS relapse will be eligible if they have previously been treated with cranial radiation (at least 1800 cGy).
  10. Ability to give informed consent.
  11. Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
  12. Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.
  13. Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L.
  14. Patients with history of allogeneic stem cell transplantation are eligible if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  15. Patients volunteer to participate in the research

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for participation in the study:

  1. Patients are evaluated below 50 scores with KPS.
  2. Evident signs suggesting that patients are potentially allergic to cytokines.
  3. Frequent infection history and recent infection is uncontrolled.
  4. Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
  5. Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.
  6. Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.
  7. Pregnancy and nursing females. HIV infection.
  8. Active hepatitis B or active hepatitis C.
  9. Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.
  10. Class III/IV cardiovascular disability according to the New York Heart Association Classification.
  11. Patients with a known history or prior diagnosis of other serious immunologic, malignant or inflammatory disease.
  12. Other situations we think not eligible for participation in the research.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737085


Locations
Layout table for location information
China, Chongqing
Southwest Hospital of Third Millitary Medical University
Chongqing, Chongqing, China, 400000
Sponsors and Collaborators
Southwest Hospital, China
Investigators
Layout table for investigator information
Principal Investigator: Jieping Chen, MD,PhD Department of Hematology, Southwest Hospital, Third Military Medical University

Layout table for additonal information
Responsible Party: Jieping Chen, Head of Hematology Department, Southwest Hospital, China
ClinicalTrials.gov Identifier: NCT02737085     History of Changes
Other Study ID Numbers: Southwest Hospital, China
First Posted: April 13, 2016    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Jieping Chen, Southwest Hospital, China:
CD19-targeted CAR-T Cell
CD20-targeted CAR-T Cell
Diffuse Large B Cell Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents